Hey. You know for all the bs I give you, you remain the undisputed biotech king of ET. So when you make a series of posts like this regarding AMTX, I take note. I always have lol. Interesting company. I've spent the last 1/2 hour looking at things. Now I'm not sure if this is important or not, but I thought I'd take the time to log in and point it out to not only you, well primarily you, but to the readers also. So no one gets too gung-ho pre-market in the blind based on your excellent track record regarding stocks like this. It may be nothing, but for what it's worth.... is this a 75% dilutive shelf registration filed on the back of that great report? https://www.sec.gov/Archives/edgar/data/1658551/000119312522006731/d273128dex31.htm VS. Current shares outstanding: https://www.sec.gov/Archives/edgar/data/1658551/000119312522006731/d273128dex31.htm Just thought I'd point that out for your thoughts before the pre-market opened. ________________________ Readers: This is why Stoney lets me get away with all the (well deserved) bs I give him. He is #1 in the bio-king dept however, that's why I spent a little time on this. ALS is a horrible disease, and dilution aside... pretty sure this company's heart is in the right place. That's my read on things. ~vz
I thought I'd take the time to log in... Vz are you having trouble with the log in? I changed my password. First time ever. It worked now I can get on easily again. I'll check that secondary you say it was just filed yest-?// I actually take that as good news that they expect the stock to run. Surely they won't drop that until they retake the price action they had before the next earn report. Why waste it?-- Could still be a great 1 week gummy.
Damn I have ACHR on my idea list-> Archer Aviation stock climbs 25% on Boeing lawsuit settlement, $215M funding
This is pretty funny- from The Street// a year ago this chump wants you in at $10 for a ride to $26 and now he gets off to " Take profits " a year later at 11? Do people pay for this? In my original buy recommendation back on December 6, 2022 I wrote that "Success in the biotechnology field can come and go so traders need to keep that in mind when they go long. Traders could long PACB around $10 risking to $7. The $26 area is our price target for now." Let's check the PACB charts and indicators again. In the updated daily bar chart of PACB, below, I can see that the shares made a brief new high for the move up last month and have been correcting lower in recent weeks, not unlike previous pullbacks the past 12 months. PACB has closed below the now cresting 50-day moving average line but remains above the rising 200-day line. The On-Balance-Volume (OBV) shows us a gentle rise the past year with some recent weakness. The Moving Average Convergence Divergence (MACD) oscillator is now slipping below the zero line into sell territory. In the weekly Japanese candlestick chart of PACB, below, I see a picture that is starting to tip lower. The latest candle shows a lower shadow but it has edged lower towards the rising 40-week moving average line. Trading volume has been light and the weekly OBV line has been stalled the past two months. The MACD oscillator is above the zero line but has crossed to the downside for a take profit sell signal.
Well Mr Street.com how about this: Cathie Wood plows $6 million into Pacific Biosciences Aug 8, 2023 Updated Aug 8, 2023 0 Not so fast! If you knew the true size of an Alien penis you would not question my abilities.
Lets break down the sincerity of the trades: 22 Cathie Wood Pacific Biosciences of California Trades Cathie Wood's position in Pacific Biosciences of California is currently worth $311 Million. That's 2.11% of their equity portfolio (16th largest holding). The investor owns 10.81% of the outstanding Pacific Biosciences of California stock. The first Pacific Biosciences of California trade was made in Q3 2017. Since then Cathie Wood bought shares seventeen more times and sold shares on eight occasions. The stake costed the investor $302 Million, netting the investor a gain of 2.9% so far.
Not a lot of Insider activity but we did have a buy in May and that would of been at these prices- in May 2023, Marshall Mohr, a Director at PACB bought 25,000.00 shares for a total of $63,500.00.
Goldman Sachs Keeps Their Buy Rating on Pacific Biosciences (PACB) Aug. 7, 2023, 01:15 AM Goldman Sachs analyst Matthew Sykes maintained a Buy rating on Pacific Biosciences (PACB – Research Report) on August 2 and set a price target of $17.00. The company’s shares closed last Friday at $12.18. Sykes covers the Healthcare sector, focusing on stocks such as Exact Sciences, Myriad Genetics, and Invitae. According to TipRanks, Sykes has an average return of -11.7% and a 41.03% success rate on recommended stocks. In addition to Goldman Sachs, Pacific Biosciences also received a Buy from Scotiabank’s Sung Ji Nam in a report issued on August 4. However, on August 2, Barclays assigned a Hold rating to Pacific Biosciences (NASDAQ: PACB).
The stock market's 'no recession' relief rally is over. Expect flat markets for the rest of the year. The "no recession relief rally" has ended for the stock market, according to Stifel's Barry Bannister. Bannister said investors should expect a flat market between now and the end of the year. "After a trading range in 2H23, we see signs of a recession, however mild, is likely is ~1Q24," Bannister said.
Pacific Biosciences of California Profile Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.